Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 62

Results For "safety"

1847 News Found

FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder
Drug Approval | October 11, 2025

FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder

UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults


Botanic Healthcare unveils PeptiGlow and LipoLush for beauty and wellness
Healthcare | October 11, 2025

Botanic Healthcare unveils PeptiGlow and LipoLush for beauty and wellness

PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration


BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
Clinical Trials | October 10, 2025

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants


Bayer and Kumquat initiate Phase I study with KRAS G12D inhibitor in patients with KRAS-mutated tumors
News | October 10, 2025

Bayer and Kumquat initiate Phase I study with KRAS G12D inhibitor in patients with KRAS-mutated tumors

First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors


Coveris and SABIC pioneer closed-loop recycling for medical packaging
Packaging | October 10, 2025

Coveris and SABIC pioneer closed-loop recycling for medical packaging

The initiative successfully demonstrates that used medical plastic packaging can be recycled and transformed back into new, contact-sensitive medical packaging


Lilly’s Omvoh shows sustained 4-year efficacy in ulcerative colitis
News | October 09, 2025

Lilly’s Omvoh shows sustained 4-year efficacy in ulcerative colitis

Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis


Lupin launches partnership program to expand global reach of PrecisionSphere injectable platform
News | October 09, 2025

Lupin launches partnership program to expand global reach of PrecisionSphere injectable platform

Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles


VectorBuilder Redefines Plasmid Standards with miniVec
R&D | October 08, 2025

VectorBuilder Redefines Plasmid Standards with miniVec

Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively


RedHill Biopharma inks $1.8 million Middle East licensing deal for Talicia
News | October 08, 2025

RedHill Biopharma inks $1.8 million Middle East licensing deal for Talicia

RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months


Lupin to build $250 million manufacturing facility in Florida
News | October 08, 2025

Lupin to build $250 million manufacturing facility in Florida

Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?